[1] 末梢閉塞性動脈疾患の治療ガイドライン(2015年度版).
[2] F. G. R. Fowkes, D. Rudan, I. Rudan, et al., Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet; 382 (9901): 1329–1340, 2013.
[3] Fontaine R, M. Kim, and R. Kieny, Surgical treatment of peripheral circulation disorders. Helv Chir Acta.; 21 (5–6): 499–533, 1954.
[4] R. B. Rutherford, J. D. Baker, C. Ernst, et al., Recommended standards for reports dealing with lower extremity ischemia: Revised version. J. Vasc. Surg.; 26 (3): 517–538, 1997.
[5] L. Norgren, W. R. Hiatt, J. A. Dormandy, et al., Inter-Society Consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg.; 45 (Supplement S): S5A–S67A, 2007.
[6] D. F. Lazarous, E. F. Unger, S. E. Epstein, et al., Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial. J. Am. Coll. Cardiol.; 36 (4): 1239–1244, 2000.
[7] L. T. Cooper Jr., W. R. Hiatt, M. A. Creager, et al., Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc.Med.; 6 (4): 235–239, 2001.
[8] R. J. Lederman, F. O. Mendelsohn, R. D. Anderson, et al., Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet; 359 (9323): 2053–2058, 2002.
[9] K. Mäkinen, H. Manninen, M. Hedman, et al., Increased Vascularity Detected by Digital Subtraction Angiography after VEGF Gene Transfer to Human Lower Limb Artery: A Randomized, Placebo-Controlled, Double-Blinded Phase II Study. Mol. Ther.; 6 (1): 127–133, 2002.
[10] S. Rajagopalan, E. R. M. III, R. J. Lederman, et al., Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease: A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Cl. Circulation; 108 (16): 1933–1938, 2003.
[11] Y. H. Kusumanto, V. van Weel, N. H. Mulder, et al., Treatment with Intramuscular Vascular Endothelial Growth Factor Gene Compared with Placebo for Patients with Diabetes Mellitus and Critical Limb Ischemia: A Double-Blind Randomized Trial. Hum. Gene Ther.; 17 (6): 683–691, 2006.
[12] H. Shigematsu, K. Yasuda, T. Iwai, et al., Randomized, double-blind, placebo-Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther.; 17 (9): 1152–1161, 2010.
[13] P. M. Grossman, F. Mendelsohn, T. D. Henry, et al., Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am. Heart J.; 153 (5): 874–880, 2007.
[14] E. Tateishi-Yuyama, H. Matsubara, T. Murohara, et al., Therapeutic angiogenesis for patients with Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet; 360 (9331): 427–435, 2002.
[15] P. P. Huang, X. FengYang, S. Z. Li, et al., Randomised comparison of G-CSF-mobilizedperipheral blood mononuclear cells versus bone marrow-mononuclear cellsfor the treatment of patients withlower limb arteriosclerosis obliterans. Thromb. Haemost.; 98 (2): 1335–1342, 2007.
[16] P. HUANG, S. LI, M. HAN, et al., Autologous Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells Improves Critical Limb Ischemia in Diabetes. Diabetes Care; 28 (9): 2155–2160, 2005.
[17] T. Bartsch, M. Brehm, T. Zeus, et al., Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (The TAM-PAD study). Clin. Res. Cardiol.; 96 (12): 891–899, 2007.
[18] G. Cobellis, A. Silvestroni, S. Lillo, et al., Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant.; 42 (10): 667–672, 2008.
[19] V. Procházka, J. Gumulec, F. Jalůvka, et al., Cell Therapy, a New Standard in Management of Chronic Critical Limb Ischemia and Foot Ulcer. Cell Transplant.; 19 (11): 1413–1424, 2010.
[20] D. Lu, B. Chen, Z. Liang, et al., Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res. Clin. Pract.; 92 (1): 26–36, 2011.
[21] D. H. Walter, H. Krankenberg, J. O. Balzer, et al., Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia a randomized-start, placebo-controlled pilot trial (PROVASA). Circ. Cardiovasc. Interv.; 4 (1): 26–37, 2011.
[22] M. D. Iafrati, J. W. Hallett, G. Geils, et al., Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J. Vasc. Surg.; 54 (6): 1650–1658, 2011.
[23] N. Idei, J. Soga, T. Hata, et al., Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia : A comparison of atherosclerotic peripheral arterial disease and buerger disease. Circ. Cardiovasc. Interv.; 4 (1): 15–25, 2011.
[24] R. J. Powell, W. A. Marston, S. A. Berceli, et al., Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial. Mol. Ther.; 20 (6): 1280–1286, 2012.
[25] D. W. Losordo, M. R. Kibbe, F. Mendelsohn, et al., A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia. Circ Cardiovasc Interv.; 5 (6): 821–830, 2012.
[26] M. Kumagai, A. Marui, Y. Tabata, et al., Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. Heart Vessels; 31 (5): 713–721, 2016.
[27] J. Belch, W. R. Hiatt, I. Baumgartner, et al., Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet; 377 (9781): 1929–1937, 2011.
[28] M. Arai, Y. Misao, H. Nagai, et al., Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ. J.; 70 (9): 1093–1098, 2006.
[29] S. Nikol, I. Baumgartner, E. Van Belle, et al., Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther.; 16 (5): 972–978, 2008.
[30] H. Maeda, J. Wu, T. Sawa, et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release; 65 (1–2): 271–284, 2000.
[31] H. Hashizume, P. Baluk, S. Morikawa, et al., Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol.; 156 (4): 1363–1380, 2000.
[32] H. Nehoff, N. N. Parayath, L. Domanovitch, et al., Nanomedicine for drug targeting: Strategies beyond the enhanced permeability and retention effect. Int. J. Nanomedicine; 9 (1): 2539–2555, 2014.
[33] I. Buschmann, M. Heil, M. Jost, et al., Influence of Inflammatory Cytokines on Arteriogenesis. Microcirculation; 10 (3–4): 371–379, 2003.
[34] M. Heil and W. Schaper, Influence of mechanical, cellular, and molecular factors on collateral artery growth (Arteriogenesis). Circ. Res.; 95 (5): 449–458, 2004.
[35] A. La Sala, L. Pontecorvo, A. Agresta, et al., Regulation of collateral blood vessel development by the innate and adaptive immune system. Trends Mol. Med.; 18 (8): 494–501, 2012.
[36] D. T. Sweet, Z. Chen, C. S. Givens, et al., Endothelial shc regulates arteriogenesis through dual control of arterial specification and inflammation via the notch and nuclear factor-k-light-chain- enhancer of activated b-cell pathways. Circ. Res.; 113 (1): 32–39, 2013.
[37] E. Stabile, M. Susan Burnett, C. Watkins, et al., Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation; 108 (2): 205–210, 2003.
[38] D. De Groot, R. T. Haverslag, G. Pasterkamp, et al., Targeted deletion of the inhibitory NF-κB p50 subunit in bone marrow-derived cells improves collateral growth after arterial occlusion. Cardiovasc. Res.; 88 (1): 179–185, 2010.
[39] G. L. Tang, D. S. Chang, R. Sarkar, et al., The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J. Vasc. Surg.; 41 (2): 312–320, 2005.
[40] Z. W. Zhuang, L. Gao, M. Murakami, et al., Arteriogenesis : Noninvasive Quantification with Multi – Detector Purpose : Methods : Results : Conclusion : Radiology; 240 (3): 698–707, 2006.
[41] Q. Li, D. Yao, J. Ma, et al., Transplantation of MSCs in Combination with Netrin-1 Improves Neoangiogenesis in a Rat Model of Hind Limb Ischemia. J. Surg. Res.; 166 (1): 162–169, 2011.
[42] A. Nagano, T. Komatsuno, H. Kasahara, et al., Evaluation of hepatocyte growth factor plasmid therapeutic effect by 99mTc-hexakis-2-methyoxy-isobutylisonitrile blood flow scintigraphy in a rat model of hind limb ischemia. Nucl. Med. Commun.; 32 (9): 818–823, 2011.
[43] H. A. Corcoran, B. E. Smith, P. Mathers, et al., Laser Doppler Imaging of Reactive Hyperemia Exposes Blood Flow Deficits in a Rat Model of Experimental Limb Ischemia. J Cardiovasc Pharmacol.; 53 (6): 446– 451, 2009.
[44] Y. Anraku, A. Kishimura, M. Oba, et al., Spontaneous Formation of Nanosized Unilamellar Polyion Complex Vesicles with Tunable Size and Properties. J. Am. Chem. Soc.; 132 (5): 1631–1636, 2010.
[45] A. Koide, A. Kishimura, K. Osada, et al., Semipermeable Polymer Vesicle (PICsome) Self-Assembled in Aqueous Medium from a Pair of Oppositely Charged Block Copolymers: Physiologically Stable Micro-/Nanocontainers of Water-Soluble Macromolecules. J. Am. Chem. Soc.; 128 (18): 5988–5989, 2006.
[46] A. Kishimura, A. Koide, K. Osada, et al., Encapsulation of myoglobin in PEGylated polyion complex vesicles made from a pair of oppositely charged block ionomers: A physiologically available oxygen carrier. Angew. Chemie - Int. Ed.; 46 (32): 6085–6088, 2007.
[47] Y. Anraku, A. Kishimura, A. Kobayashi, et al., Size-controlled long-circulating PICsome as a ruler to measure critical cut-off disposition size into normal and tumor tissues. Chem. Commun.; 47 (21): 6054–6056, 2011.
[48] A. Kishimura, Development of polyion complex vesicles (PICsomes) from block copolymers for biomedical applications. Polym. J.; 45 (9): 892–897, 2013.
[49] T. Shirasu, H. Koyama, Y. Miura, et al., Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats. PLoS One; 11 (6): e0157813, 2016.
[50] R. Taniguchi, Y. Miura, H. Koyama, et al., Adequately-Sized Nanocarriers Allow Sustained Targeted Drug Delivery to Neointimal Lesions in Rat Arteries. Mol. Pharm.; 13 (6): 2108–2116, 2016.
[51] M. Heil, I. Eitenmüller, T. Schmitz-Rixen, et al., Arteriogenesis versus angiogenesis: Similarities and differences. J. Cell. Mol. Med.; 10 (1): 45–55, 2006.
[52] Y. Lee, T. Ishii, H. Cabral, et al., Charge-conversional polyionic complex micelles-efficient nanocarriers for protein delivery into cytoplasm. Angew. Chemie - Int. Ed.; 48 (29): 5309–5312, 2009.
[53] Y. Lee, S. Fukushima, Y. Bae, et al., A Protein Nanocarrier from Charge-Conversion Polymer in Response to Endosomal pH. J. Am. Chem. Soc.; 129 (17): 5362–5363, 2007.
[54] UniProt BLAST. Https://www.uniprot.org/blast/; n.d.
[55] A. Nishiyama, H. Koyama, T. Miyata, et al., Therapeutic site selection is important for the successful development of collateral vessels. J. Vasc. Surg.; 62 (1): 190–199, 2015.
[56] B. M. Prior, P. G. Lloyd, J. Ren, et al., Time course of changes in collateral blood flow and isolated vessel size and gene expression after femoral artery occlusion in rats. Am J Physiol Hear. Circ Physiol; 287 (6): 2434–2447, 2004.
[57] C. W. Lee, E. Stabile, T. Kinnaird, et al., Temporal Patterns of Gene Expression After Acute Hindlimb Ischemia in Mice Insights Into the Genomic Program for Collateral Vessel Development. J. Am. Coll. Cardiol.; 43 (3): 474–482, 2004.
[58] A. Kim, Y. Miura, T. Ishii, et al., Intracellular Delivery of Charge-Converted Monoclonal Antibodies by Combinatorial Design of Block/Homo Polyion Complex Micelles. Biomacromolecules; 17 (2): 446–453, 2016.
[59] C. A. Dinarello, K. Muegge, and S. K. Durum, Measurement of soluble and membrane-bound interleukin 1 using a fibroblast bioassay. Curr. Protoc. Immunol.; Supplement Unit 6.2.1-7, 2000.
[60] S. Herzog, H. Sager, E. Khmelevski, et al., Collateral arteries grow from preexisting anastomoses in the rat hindlimb. Am. J. Physiol. Heart Circ. Physiol.; 283 (5): H2012-20, 2002.
[61] A. W. Clowes, M. M. Clowes, J. Fingerle, et al., Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol.; 14 (Suppl 6): S12-15, 1989.
[62] A. Takahashi, Y. Yamamoto, M. Yasunaga, et al., NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci.; 104 (7): 920–925, 2013.
[63] G. Yan and A. G. Kleber, Changes in Extracellular and Intracellular pH in Ischemic Rabbit Papillary Muscle. Circ. Res.; 71 (2): 460–471, 1992.
[64] M. Nemoto, H. Koyama, A. Nishiyama, et al., Adequate Selection of a Therapeutic Site Enables Efficient Development of Collateral Vessels in Angiogenic Treatment With Bone Marrow Mononuclear Cells. J. Am. Heart Assoc.; 4 (9): e002287, 2015.
[65] K. Shiraishi, K. Kawano, Y. Maitani, et al., Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T1-relaxivities and blood circulation characteristics. J. Control. Release; 148 (2): 160–167, 2010.